Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.

Iksuda Therapeutics develops next-generation antibody-drug conjugate (ADC) therapies to target cancers that are difficult to treat, or resistant to current treatments, without damaging healthy cells.